Morgan Janes joined the T1D Fund as an Associate in October 2024. Prior to joining the Fund, she earned her Ph.D. at MIT, where she was an NSF Fellow in the laboratory of Samir Mitragotri. Her thesis research focused on developing simple, bioinspired materials for vaccine delivery.

Morgan previously held fellowships at MPM Capital, supporting therapeutics company ideation, and at Artis Ventures, where she conducted due diligence on early-stage biotech and healthcare opportunities.

She received her B.S. in Bioengineering from the University of Maryland, with a research focus in tissue engineering and biomaterials.

Valerie Su joined the T1D Fund in August 2024. Prior to joining the Fund, she worked at Sanofi as a Scientist, advancing early drug discovery programs in autoimmune disease across multiple modalities, including antibodies, small molecules, and NANOBODY® molecules. She also completed a six-month internal internship in External Innovation, where she evaluated the competitive landscape for transplant therapies and helped prioritize external opportunities aligned with Sanofi’s portfolio strategy.

Valerie earned her Ph.D. in Pharmacology from Yale University in the laboratory of David Calderwood, where she studied molecular regulators of integrin and cerebral cavernous malformation signaling pathways. She received her B.A. in Molecular and Cell Biology from the University of California, Berkeley.